Sort by
Items per page

Send to

Choose Destination

Search results

Items: 49


Characterizing Cellular Responses During Oncolytic Maraba Virus Infection.

Hassanzadeh G, Naing T, Graber T, Jafarnejad SM, Stojdl DF, Alain T, Holcik M.

Int J Mol Sci. 2019 Jan 29;20(3). pii: E580. doi: 10.3390/ijms20030580.


Preclinical evaluation of a MAGE-A3 vaccination utilizing the oncolytic Maraba virus currently in first-in-human trials.

Pol JG, Acuna SA, Yadollahi B, Tang N, Stephenson KB, Atherton MJ, Hanwell D, El-Warrak A, Goldstein A, Moloo B, Turner PV, Lopez R, LaFrance S, Evelegh C, Denisova G, Parsons R, Millar J, Stoll G, Martin CG, Pomoransky J, Breitbach CJ, Bramson JL, Bell JC, Wan Y, Stojdl DF, Lichty BD, McCart JA.

Oncoimmunology. 2018 Sep 19;8(1):e1512329. doi: 10.1080/2162402X.2018.1512329. eCollection 2019.


Development and applications of oncolytic Maraba virus vaccines.

Pol JG, Atherton MJ, Bridle BW, Stephenson KB, Le Boeuf F, Hummel JL, Martin CG, Pomoransky J, Breitbach CJ, Diallo JS, Stojdl DF, Bell JC, Wan Y, Lichty BD.

Oncolytic Virother. 2018 Nov 26;7:117-128. doi: 10.2147/OV.S154494. eCollection 2018. Review.


Transforming the prostatic tumor microenvironment with oncolytic virotherapy.

Atherton MJ, Stephenson KB, Tzelepis F, Bakhshinyan D, Nikota JK, Son HH, Jirovec A, Lefebvre C, Dvorkin-Gheva A, Ashkar AA, Wan Y, Stojdl DF, Belanger EC, Breau RH, Bell JC, Saad F, Singh SK, Diallo JS, Lichty BD.

Oncoimmunology. 2018 Mar 27;7(7):e1445459. doi: 10.1080/2162402X.2018.1445459. eCollection 2018.


Genome-wide RNAi Screening to Identify Host Factors That Modulate Oncolytic Virus Therapy.

Allan KJ, Mahoney DJ, Baird SD, Lefebvre CA, Stojdl DF.

J Vis Exp. 2018 Apr 3;(134). doi: 10.3791/56913.


Neoadjuvant oncolytic virotherapy before surgery sensitizes triple-negative breast cancer to immune checkpoint therapy.

Bourgeois-Daigneault MC, Roy DG, Aitken AS, El Sayes N, Martin NT, Varette O, Falls T, St-Germain LE, Pelin A, Lichty BD, Stojdl DF, Ungerechts G, Diallo JS, Bell JC.

Sci Transl Med. 2018 Jan 3;10(422). pii: eaao1641. doi: 10.1126/scitranslmed.aao1641.


Activating Peripheral Innate Immunity Enables Safe and Effective Oncolytic Virotherapy in the Brain.

Balathasan L, Tang VA, Yadollahi B, Brun J, Labelle M, Lefebvre C, Swift SL, Stojdl DF.

Mol Ther Oncolytics. 2017 Sep 15;7:45-56. doi: 10.1016/j.omto.2017.09.004. eCollection 2017 Dec 15.


Customized Viral Immunotherapy for HPV-Associated Cancer.

Atherton MJ, Stephenson KB, Pol J, Wang F, Lefebvre C, Stojdl DF, Nikota JK, Dvorkin-Gheva A, Nguyen A, Chen L, Johnson-Obaseki S, Villeneuve PJ, Diallo JS, Dimitroulakos J, Wan Y, Lichty BD.

Cancer Immunol Res. 2017 Oct;5(10):847-859. doi: 10.1158/2326-6066.CIR-17-0102. Epub 2017 Sep 14.


NK-Cell Recruitment Is Necessary for Eradication of Peritoneal Carcinomatosis with an IL12-Expressing Maraba Virus Cellular Vaccine.

Alkayyal AA, Tai LH, Kennedy MA, de Souza CT, Zhang J, Lefebvre C, Sahi S, Ananth AA, Mahmoud AB, Makrigiannis AP, Cron GO, Macdonald B, Marginean EC, Stojdl DF, Bell JC, Auer RC.

Cancer Immunol Res. 2017 Mar;5(3):211-221. doi: 10.1158/2326-6066.CIR-16-0162. Epub 2017 Feb 3.


Oncolytic virus synergizes with Smac mimetic compounds to induce rhabdomyosarcoma cell death in a syngeneic murine model.

Dobson CC, Naing T, Beug ST, Faye MD, Chabot J, St-Jean M, Walker DE, LaCasse EC, Stojdl DF, Korneluk RG, Holcik M.

Oncotarget. 2017 Jan 10;8(2):3495-3508. doi: 10.18632/oncotarget.13849.


Complement inhibition enables tumor delivery of LCMV glycoprotein pseudotyped viruses in the presence of antiviral antibodies.

Evgin L, Ilkow CS, Bourgeois-Daigneault MC, de Souza CT, Stubbert L, Huh MS, Jennings VA, Marguerie M, Acuna SA, Keller BA, Lefebvre C, Falls T, Le Boeuf F, Auer RA, Lambris JD, McCart JA, Stojdl DF, Bell JC.

Mol Ther Oncolytics. 2016 Nov 16;3:16027. eCollection 2016.


High-throughput screening to enhance oncolytic virus immunotherapy.

Allan KJ, Stojdl DF, Swift SL.

Oncolytic Virother. 2016 Apr 5;5:15-25. doi: 10.2147/OV.S66217. eCollection 2016. Review.


Big Data Offers Novel Insights for Oncolytic Virus Immunotherapy.

Swift SL, Stojdl DF.

Viruses. 2016 Feb 5;8(2). pii: E45. doi: 10.3390/v8020045. Review.


Programmable insect cell carriers for systemic delivery of integrated cancer biotherapy.

Roy DG, Power AT, Bourgeois-Daigneault MC, Falls T, Ferreira L, Stern A, Tanese de Souza C, McCart JA, Stojdl DF, Lichty BD, Atkins H, Auer RC, Bell JC, Le Boeuf F.

J Control Release. 2015 Dec 28;220(Pt A):210-221. doi: 10.1016/j.jconrel.2015.10.030. Epub 2015 Oct 19.


Hexokinase 2 controls cellular stress response through localization of an RNA-binding protein.

Courteau L, Crasto J, Hassanzadeh G, Baird SD, Hodgins J, Liwak-Muir U, Fung G, Luo H, Stojdl DF, Screaton RA, Holcik M.

Cell Death Dis. 2015 Aug 6;6:e1837. doi: 10.1038/cddis.2015.209.


Reciprocal cellular cross-talk within the tumor microenvironment promotes oncolytic virus activity.

Ilkow CS, Marguerie M, Batenchuk C, Mayer J, Ben Neriah D, Cousineau S, Falls T, Jennings VA, Boileau M, Bellamy D, Bastin D, de Souza CT, Alkayyal A, Zhang J, Le Boeuf F, Arulanandam R, Stubbert L, Sampath P, Thorne SH, Paramanthan P, Chatterjee A, Strieter RM, Burdick M, Addison CL, Stojdl DF, Atkins HL, Auer RC, Diallo JS, Lichty BD, Bell JC.

Nat Med. 2015 May;21(5):530-6. doi: 10.1038/nm.3848. Epub 2015 Apr 20.


Virus therapy for cancer.

Mahoney DJ, Stojdl DF, Laird G.

Sci Am. 2014 Nov;311(5):54-9. No abstract available.


Going viral with cancer immunotherapy.

Lichty BD, Breitbach CJ, Stojdl DF, Bell JC.

Nat Rev Cancer. 2014 Aug;14(8):559-67. doi: 10.1038/nrc3770. Epub 2014 Jul 3. Review.


Maraba MG1 virus enhances natural killer cell function via conventional dendritic cells to reduce postoperative metastatic disease.

Zhang J, Tai LH, Ilkow CS, Alkayyal AA, Ananth AA, de Souza CT, Wang J, Sahi S, Ly L, Lefebvre C, Falls TJ, Stephenson KB, Mahmoud AB, Makrigiannis AP, Lichty BD, Bell JC, Stojdl DF, Auer RC.

Mol Ther. 2014 Jul;22(7):1320-1332. doi: 10.1038/mt.2014.60. Epub 2014 Apr 3.


Maraba virus as a potent oncolytic vaccine vector.

Pol JG, Zhang L, Bridle BW, Stephenson KB, Rességuier J, Hanson S, Chen L, Kazdhan N, Bramson JL, Stojdl DF, Wan Y, Lichty BD.

Mol Ther. 2014 Feb;22(2):420-429. doi: 10.1038/mt.2013.249. Epub 2013 Oct 25.


Triptolide-mediated inhibition of interferon signaling enhances vesicular stomatitis virus-based oncolysis.

Ben Yebdri F, Van Grevenynghe J, Tang VA, Goulet ML, Wu JH, Stojdl DF, Hiscott J, Lin R.

Mol Ther. 2013 Nov;21(11):2043-53. doi: 10.1038/mt.2013.187. Epub 2013 Aug 28.


Molecular pathways: multimodal cancer-killing mechanisms employed by oncolytic vesiculoviruses.

Mahoney DJ, Stojdl DF.

Clin Cancer Res. 2013 Feb 15;19(4):758-63. doi: 10.1158/1078-0432.CCR-11-3149. Epub 2012 Dec 26. Review.


Functional genomic screening to enhance oncolytic virotherapy.

Mahoney DJ, Stojdl DF.

Br J Cancer. 2013 Feb 5;108(2):245-9. doi: 10.1038/bjc.2012.467. Epub 2012 Nov 20. Review.


Harnessing oncolytic virus-mediated antitumor immunity in an infected cell vaccine.

Lemay CG, Rintoul JL, Kus A, Paterson JM, Garcia V, Falls TJ, Ferreira L, Bridle BW, Conrad DP, Tang VA, Diallo JS, Arulanandam R, Le Boeuf F, Garson K, Vanderhyden BC, Stojdl DF, Lichty BD, Atkins HL, Parato KA, Bell JC, Auer RC.

Mol Ther. 2012 Sep;20(9):1791-9. doi: 10.1038/mt.2012.128. Epub 2012 Jul 3.


Oncolytic Vaccinia virus safely and effectively treats skin tumors in mouse models of xeroderma pigmentosum.

Brun J, Mahoney DJ, Le Boeuf F, Lefebvre C, Sanaei CA, Falls T, Mccart JA, Stojdl DF.

Int J Cancer. 2013 Feb 1;132(3):726-31. doi: 10.1002/ijc.27695. Epub 2012 Sep 28.


Fighting fire with fire: rewiring tumor cells for oncolytic virotherapy.

Mahoney DJ, Stojdl DF.

Future Oncol. 2012 Mar;8(3):219-21. doi: 10.2217/fon.12.2. No abstract available.


Virus-tumor interactome screen reveals ER stress response can reprogram resistant cancers for oncolytic virus-triggered caspase-2 cell death.

Mahoney DJ, Lefebvre C, Allan K, Brun J, Sanaei CA, Baird S, Pearce N, Grönberg S, Wilson B, Prakesh M, Aman A, Isaac M, Mamai A, Uehling D, Al-Awar R, Falls T, Alain T, Stojdl DF.

Cancer Cell. 2011 Oct 18;20(4):443-56. doi: 10.1016/j.ccr.2011.09.005.


SMG1 and NIK regulate apoptosis induced by Smac mimetic compounds.

Cheung HH, St Jean M, Beug ST, Lejmi-Mrad R, LaCasse E, Baird SD, Stojdl DF, Screaton RA, Korneluk RG.

Cell Death Dis. 2011 Apr 14;2:e146. doi: 10.1038/cddis.2011.25.


Potentiating oncolytic viruses by targeted drug intervention.

Mahoney DJ, Stojdl DF.

Curr Opin Mol Ther. 2010 Aug;12(4):394-402. Review.


Identification of genetically modified Maraba virus as an oncolytic rhabdovirus.

Brun J, McManus D, Lefebvre C, Hu K, Falls T, Atkins H, Bell JC, McCart JA, Mahoney D, Stojdl DF.

Mol Ther. 2010 Aug;18(8):1440-9. doi: 10.1038/mt.2010.103. Epub 2010 Jun 15.


A call to arms: using RNAi screening to improve oncolytic viral therapy.

Mahoney DJ, Stojdl DF.

Cytokine Growth Factor Rev. 2010 Apr-Jun;21(2-3):161-7. doi: 10.1016/j.cytogfr.2010.02.013. Epub 2010 Mar 6. Review.


Efficacy of systemically administered oncolytic vaccinia virotherapy for malignant gliomas is enhanced by combination therapy with rapamycin or cyclophosphamide.

Lun XQ, Jang JH, Tang N, Deng H, Head R, Bell JC, Stojdl DF, Nutt CL, Senger DL, Forsyth PA, McCart JA.

Clin Cancer Res. 2009 Apr 15;15(8):2777-88. doi: 10.1158/1078-0432.CCR-08-2342. Epub 2009 Apr 7.


Chemical targeting of the innate antiviral response by histone deacetylase inhibitors renders refractory cancers sensitive to viral oncolysis.

Nguyên TL, Abdelbary H, Arguello M, Breitbach C, Leveille S, Diallo JS, Yasmeen A, Bismar TA, Kirn D, Falls T, Snoulten VE, Vanderhyden BC, Werier J, Atkins H, Vähä-Koskela MJ, Stojdl DF, Bell JC, Hiscott J.

Proc Natl Acad Sci U S A. 2008 Sep 30;105(39):14981-6. doi: 10.1073/pnas.0803988105. Epub 2008 Sep 24.


Targeted inflammation during oncolytic virus therapy severely compromises tumor blood flow.

Breitbach CJ, Paterson JM, Lemay CG, Falls TJ, McGuire A, Parato KA, Stojdl DF, Daneshmand M, Speth K, Kirn D, McCart JA, Atkins H, Bell JC.

Mol Ther. 2007 Sep;15(9):1686-93. Epub 2007 Jun 19.


Carrier cell-based delivery of an oncolytic virus circumvents antiviral immunity.

Power AT, Wang J, Falls TJ, Paterson JM, Parato KA, Lichty BD, Stojdl DF, Forsyth PA, Atkins H, Bell JC.

Mol Ther. 2007 Jan;15(1):123-30.


Vesicular stomatitis virus: a potential therapeutic virus for the treatment of hematologic malignancy.

Lichty BD, Stojdl DF, Taylor RA, Miller L, Frenkel I, Atkins H, Bell JC.

Hum Gene Ther. 2004 Sep;15(9):821-31.


Vesicular stomatitis virus: re-inventing the bullet.

Lichty BD, Power AT, Stojdl DF, Bell JC.

Trends Mol Med. 2004 May;10(5):210-6. Review.


VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents.

Stojdl DF, Lichty BD, tenOever BR, Paterson JM, Power AT, Knowles S, Marius R, Reynard J, Poliquin L, Atkins H, Brown EG, Durbin RK, Durbin JE, Hiscott J, Bell JC.

Cancer Cell. 2003 Oct;4(4):263-75.


An integrated stress response regulates amino acid metabolism and resistance to oxidative stress.

Harding HP, Zhang Y, Zeng H, Novoa I, Lu PD, Calfon M, Sadri N, Yun C, Popko B, Paules R, Stojdl DF, Bell JC, Hettmann T, Leiden JM, Ron D.

Mol Cell. 2003 Mar;11(3):619-33.


Oncolytic viruses: programmable tumour hunters.

Bell JC, Garson KA, Lichty BD, Stojdl DF.

Curr Gene Ther. 2002 May;2(2):243-54. Review.


Different host-cell shutoff strategies related to the matrix protein lead to persistence of vesicular stomatitis virus mutants on fibroblast cells.

Desforges M, Charron J, Bérard S, Beausoleil S, Stojdl DF, Despars G, Laverdière B, Bell JC, Talbot PJ, Stanners CP, Poliquin L.

Virus Res. 2001 Jul;76(1):87-102.


The murine double-stranded RNA-dependent protein kinase PKR is required for resistance to vesicular stomatitis virus.

Stojdl DF, Abraham N, Knowles S, Marius R, Brasey A, Lichty BD, Brown EG, Sonenberg N, Bell JC.

J Virol. 2000 Oct;74(20):9580-5.


Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus.

Stojdl DF, Lichty B, Knowles S, Marius R, Atkins H, Sonenberg N, Bell JC.

Nat Med. 2000 Jul;6(7):821-5.


SR protein kinases: the splice of life.

Stojdl DF, Bell JC.

Biochem Cell Biol. 1999;77(4):293-8. Review.


Characterization of transgenic mice with targeted disruption of the catalytic domain of the double-stranded RNA-dependent protein kinase, PKR.

Abraham N, Stojdl DF, Duncan PI, Méthot N, Ishii T, Dubé M, Vanderhyden BC, Atkins HL, Gray DA, McBurney MW, Koromilas AE, Brown EG, Sonenberg N, Bell JC.

J Biol Chem. 1999 Feb 26;274(9):5953-62.


The murine PKR tumor suppressor gene is rearranged in a lymphocytic leukemia.

Abraham N, Jaramillo ML, Duncan PI, Méthot N, Icely PL, Stojdl DF, Barber GN, Bell JC.

Exp Cell Res. 1998 Nov 1;244(2):394-404.


The Clk2 and Clk3 dual-specificity protein kinases regulate the intranuclear distribution of SR proteins and influence pre-mRNA splicing.

Duncan PI, Stojdl DF, Marius RM, Scheit KH, Bell JC.

Exp Cell Res. 1998 Jun 15;241(2):300-8.


In vivo regulation of alternative pre-mRNA splicing by the Clk1 protein kinase.

Duncan PI, Stojdl DF, Marius RM, Bell JC.

Mol Cell Biol. 1997 Oct;17(10):5996-6001.


Supplemental Content

Loading ...
Support Center